ReviewFrontiers in neuroscience2014
A review of β-amyloid neuroimaging in Alzheimer's disease.
Review in Frontiers in neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.Frontiers in aging neuroscience · 2023Pooled it
- Deep Learning-based Synthesis of Amyloid PET Images from Structural MRI in Alzheimer's Disease.Molecular imaging and biology · 2026Article
- Multivariate Analyses with Two-Step Dimension Reduction for an Association Study BetweenBioengineering (Basel, Switzerland) · 2025Article
- Unveiling the therapeutic potential ofFrontiers in pharmacology · 2024Article
- Interactions of Cellular Energetic Gene Clusters in the Alzheimer's Mouse Brain.Molecular neurobiology · 2024Article
- Two-Photon Fluorescent Probes for Amyloid-β Plaques Imaging In Vivo.Molecules (Basel, Switzerland) · 2023Review
- Neurodegenerative Changes in the Brains of the 5xFAD Alzheimer's Disease Model Mice Investigated by High-Field and High-Resolution Magnetic Resonance Imaging and Multi-Nuclei Magnetic Resonance Spectroscopy.International journal of molecular sciences · 2023Article
- Microstructural mapping of dentate gyrus pathology in Alzheimer's disease: A 16.4 Tesla MRI study.NeuroImage. Clinical · 2023Article
- Article
- Age-dependent microstructure alterations in 5xFAD mice by high-resolution diffusion tensor imaging.Frontiers in neuroscience · 2022Article
- Donepezil-loaded PLGA-b-PEG Nanoparticles Enhance the Learning and Memory Function of Beta-Amyloid Rat Model of Alzheimer's Disease.Noro psikiyatri arsivi · 2022Article
- Toll-Like Receptor 4: A Promising Therapeutic Target for Alzheimer's Disease.Mediators of inflammation · 2022Review
- Impact of Donepezil on Brain Glucose Metabolism Assessed Using [Frontiers in neuroscience · 2022Article
- Saturation Transfer MRI for Detection of Metabolic and Microstructural Impairments Underlying Neurodegeneration in Alzheimer's Disease.Brain sciences · 2021Review
- Changes in LASSI-L performance over time among older adults with amnestic MCI and amyloid positivity: A preliminary study.Journal of psychiatric research · 2021Article
- Fluorine-19 Magnetic Resonance Imaging for Detection of Amyloid β Oligomers Using a Keto Form of Curcumin Derivative in a Mouse Model of Alzheimer's Disease.Molecules (Basel, Switzerland) · 2021Article
- Immunomagnetic Reduction Detects Plasma AβNeurology and therapy · 2020Review
- Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Trends in the public health significance, definitions of disease, and implications for prevention of Alzheimer's disease.Current epidemiology reports · 2020Article
- Regional times to equilibria and their impact on semi-quantification of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common cause of dementia worldwide. As advancing age is the greatest risk factor for developing AD, the number of those afflicted is expected to increase markedly with the aging of the world's population. The inability to definitively diagnose AD until autopsy remains an impediment to establishing effective targeted treatments. Neuroimaging has enabled in vivo visualization of pathological changes in the brain associated with the disease, providing a greater understanding of its pathophysiological development and progression. However, neuroimaging biomarkers do not yet offer clear advantages over current clinical diagnostic criteria for them to be accepted into routine clinical use. Nonetheless, current insights from neuroimaging combined with the elucidation of biochemical and molecular processes in AD are informing the ongoing development of new imaging techniques and their application. Much of this research has been greatly assisted by the availability of transgenic mouse models of AD. In this review we summarize the main efforts of neuroimaging in AD in humans and in mouse models, with a specific focus on β-amyloid, and discuss the potential of new applications and novel approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.